Wesper Journal

GLP-1 receptor agonists, such as Zepbound (tirzepatide), represent a groundbreaking advancement in managing Obstructive Sleep Apnea (OSA). These medications not only promote significant weight loss, which reduces airway obstruction but may also improve neuromuscular control of breathing. Traditionally treated with mechanical interventions like CPAP, OSA care now benefits from a more comprehensive approach. The FDA-approved Zepbound has demonstrated substantial reductions in apnea events and weight-related contributors to OSA, offering an alternative for patients who struggle with CPAP therapy. Advanced tools like Wesper, a wearable sleep monitoring system, further enhance OSA management by providing real-time insights and personalized feedback. This dual-action approach—combining pharmaceutical innovation with cutting-edge technology—signals a transformative shift in sleep medicine, offering hope for millions affected by OSA worldwide.